0001193125-26-225142
SEC filingRevenue more than doubled year-over-year as neffy commercialization advanced, but operating and net losses widened due to continued investment in launch infrastructure and the absence of offsetting non-operating cash inflows.
Revenue for Q1 FY2026 totaled $22.7 million, a 184.5% increase from $8.0 million in Q1 FY2025. This growth reflects the continued commercial rollout of neffy in the United States following FDA approval in August 2024. As noted in Management’s Discussion, the company expects product revenues to fluctuate in future periods as the commercial launch progresses — underscoring the early-stage, demand-building nature of this revenue stream.
Operating income was -$60.1 million, compared to -$37.2 million in the prior-year quarter. Net income was -$60.6 million, versus -$33.9 million in Q1 FY2025. These widening losses are consistent with the company’s long-standing pattern: since inception, ARS has incurred significant operating losses and negative cash flows from operations. The magnitude of loss expansion reflects continued investment in commercial infrastructure, including sales force deployment and marketing activities, as the company advances toward broader insurance coverage — a factor management identifies as critical for accelerating adoption in the high-volume epinephrine market.
Diluted EPS was -$0.61, compared to -$0.35 in Q1 FY2025. The decline reflects both the larger net loss and an increase in weighted-average diluted shares outstanding, consistent with the company’s capital structure evolution during its commercial transition phase.
Net cash used in operating activities was -$44.9 million, up from -$40.7 million in Q1 FY2025. This reflects intensified commercial investment without offsetting non-operating cash inflows — such as maturities of short-term investments or financing proceeds — during the quarter. Capital expenditures remained at $0, reinforcing the company’s capital-light commercial execution model. As stated in Management’s Discussion, liquidity remains sourced primarily from prior financings, and the company continues to operate under conditions of negative cash flow from operations.
The company previously disclosed that certain inventory components were purchased pre-FDA approval and expensed as R&D, resulting in zero-cost inventory components. As these components are consumed in commercial production and sold, cost of goods sold reflects a lower average per-unit material cost — a dynamic expected to normalize as those components are substantially consumed by the second half of 2026. This structural feature influences near-term gross margin behavior but is not quantified in the authoritative financial packet and therefore not restated numerically here.